Modality
mRNA
MOA
PD-L1i
Target
CDK2
Pathway
PI3K/AKT
SCLC
Development Pipeline
Preclinical
Aug 2019
→ Jul 2029
PreclinicalCurrent
NCT06970407
2,163 pts·SCLC
2019-08→2029-07·Recruiting
NCT06107366
1,386 pts·SCLC
2024-07→2028-01·Active
3,549 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-01-271.8y awayInterim· SCLC
2029-07-153.3y awayInterim· SCLC
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Preclinical
Recruit…
Preclinical
Active
Catalysts
Interim
2028-01-27 · 1.8y away
SCLC
Interim
2029-07-15 · 3.3y away
SCLC
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06970407 | Preclinical | SCLC | Recruiting | 2163 | PANSS |
| NCT06107366 | Preclinical | SCLC | Active | 1386 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| AMG-415 | Amgen | Phase 1 | CDK2 |